Notice of Upcoming PCORI Funding Announcement

Key Dates

  • PFA Opens
    May 7, 2024
  • Applicant Town Hall
    May 13, 2024; 11:30 am (ET)
  • Letter of Intent (LOI) Deadline
    June 4, 2024; 5 pm (ET)
  • LOI Status Notification
    July 2, 2024
  • Application Deadline
    Sept. 4, 2024; 5 pm (ET)

The Patient-Centered Outcomes Research Institute (PCORI) intends to release a Phased Large Awards for Comparative Effectiveness Research (PLACER) PCORI Funding Announcement (PFA) on May 7, 2024 seeking to fund high-quality patient-centered comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, families, caregivers and the broader health and healthcare community and for which there is insufficient evidence. This preannouncement is provided to allow potential applicants additional time to identify collaborators; obtain patient, community and stakeholder input on potential studies; and create responsive, high-quality applications.

Investigators must propose an individual-level or cluster randomized controlled trial of significant scale and scope for this PFA. The proposed trials should address critical decisional dilemmas that require important new evidence about the comparative clinical effectiveness of available interventions. Proposed studies should compare interventions that already have robust evidence of efficacy and are in current use. If efficacy is not well established, then widespread use must be documented. Clinical interventions (such as medications, diagnostic tests or procedures) and delivery system interventions (such as workforce, technologies and healthcare service delivery designs) are appropriate for these studies. 

This funding announcement anticipates that proposed research projects will require two phases of funding. The initial phase of funding supports a distinct feasibility phase intended for purposes of study refinement, infrastructure establishment, patient and stakeholder engagement and feasibility testing of study operations, including the ability to recruit and enroll participants successfully. Using the feasibility phase to establish evidence of an intervention’s efficacy or effect size is not permitted. Approval to proceed to the second phase will be contingent on achieving specific milestones and deliverables established for the feasibility phase.

This funding opportunity seeks applications addressing any of the National Priorities for Health listed below. To be considered responsive, applications must propose research meeting the distinctive requirements of this PFA and address at least one of the following National Priorities for Health:

  • Increase Evidence for Existing Interventions and Emerging Innovations in Health
    • Goal: Strengthen and expand ongoing comparative clinical effectiveness research focused on both existing interventions and emerging innovations to improve healthcare practice, health outcomes and health equity.
  • Achieve Health Equity 
    • Goal: Expand stakeholder engagement, research and dissemination approaches that lead to continued progress toward achieving health equity in the United States. 
  • Accelerate Progress Toward an Integrated Learning Health System 
    • Goal: Foster actionable, timely, place-based and transformative improvements in patient-centered experiences, care provision and ultimately improved health outcomes through collaborative, multisectoral research to support a health system that understands and serves the needs and preferences of individuals.

In their Letter of Intent (LOI) — and in their full application if invited to submit one — applicants will be asked to select one of the National Priorities for Health above as primary, and a secondary and/or tertiary National Priority for Health if relevant.

PCORI's Topic Themes are also included in this funding opportunity. Applicants have the option to choose up to three Topic Themes based on how their proposed research aligns with the themes. However, aligning with a Topic Theme is not required. The National Priorities for Health and Topic Themes will assist PCORI in determining the optimal review pathway for the proposed research.

Meaningful patient and stakeholder engagement is viewed as an essential component of funded PLACER studies, and the feasibility phase provides an opportunity to further develop engagement plans and activities. Applicants’ use of multiple approaches that occur along a continuum of engagement from input to shared leadership is encouraged.

Considering the scale, complexity and scope of trials being solicited under this PFA, PCORI requires that applications include shared trial leadership by a data coordinating center to provide an independent role in study leadership, advising on the analytical, statistical and data management aspects of both study phases. PCORI also requires that applications include experienced engagement leadership with demonstrated experience in patient and stakeholder engagement in large research studies or projects. Investigators may request up to $2 million in direct costs for a feasibility phase up to 18 months in duration, with up to $20 million in direct costs for continuation to a full-scale study phase up to five years in duration. Total direct costs for the full application should not exceed $22 million. 

This funding opportunity will be reposted for Cycle 3 2024.

Key Dates

Online System Opens
May 7, 2024
Applicant Town Hall
View Event
Letter of Intent Deadline
June 4, 2024, 5 pm (ET)
Letter of Intent Status Notification
July 2, 2024
Application Deadline
Sept. 4, 2024, 5 pm (ET)
Merit Review
November 2024
Awards Announced
April 2025
Earliest Start Date
August 2025

Funds and Project Period

Funds Available Up To
$200 million
Total Direct Costs

$22 million

-- Feasibility phase: $2 million
-- Full-scale study phase: $20 million
Maximum Project Period

6.5 years

-- Feasibility phase: 1.5 years
-- Full-scale study phase: 5 years


Award Types